Immunosuppression in the sensitized heart transplant recipient

Current Opinion in Organ Transplantation

Volumn 15, Issue 5, 2010, Pages 650-656

  Eckman, Peter M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

alloimmunization; heart transplantation; immunosuppression; sensitized

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; ECULIZUMAB; HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LF 150195; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANEL REACTIVE ANTIBODY; PEXELIZUMAB; PLACEBO; RAPAMYCIN; RITUXIMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANTIBODY PRODUCTION; ANTIBODY TITER; B LYMPHOCYTE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CD4+ CD25+ T LYMPHOCYTE; CLINICAL TRIAL; COMPETITIVE INHIBITION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; GRAFT RECIPIENT; HEART ASSIST DEVICE; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER TRANSPLANTATION; NONHUMAN; OUTCOME ASSESSMENT; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PLASMAPHERESIS; REVIEW; SENSITIZATION; SYSTEMATIC DESENSITIZATION;

ASSISTED CIRCULATION; B-LYMPHOCYTES; DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; ISOANTIGENS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957593140     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32833de9b2     Document Type: Review

References (74)

1. Nwakanma LU, Williams JA, Weiss E.S., et al. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg 2007; 84: 1556-1562; discussion 1562-1563.
2. Gonzalez-Stawinski G.V., Cook DJ, Chang A.S., et al. Ventricular assist devices and aggressive immunosuppression: looking beyond overall survival. J Heart Lung Transplant 2006; 25: 613-618.
3. Kobashigawa J, Mehra M, West L., et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant 2009; 28: 213-225.
4. Eckman PM, Hanna M, Taylor D.O., et al. Management of the sensitized adult heart transplant candidate. Clin Transplant 2010; May 10 [Epub ahead of print]
5. Velez M, Johnson MR Management of allosensitized cardiac transplant candidates. Transplant Rev (Orlando) 2009; 23: 235-247.
6. Baldwin WM, Valujskikh A, Fairchild RL Antibody-mediated rejection: emergence of animal models to answer clinical questions. Am J Transplant 2010; 10: 1135-1142.
7. Kfoury AG, Hammond ME Controversies in defining cardiac antibody- mediated rejection: need for updated criteria. J Heart Lung Transplant 2010; 29: 389-394.
8. Singh N, Pirsch J, Samaniego M. Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev (Orlando) 2009; 23: 34-46.
9. Tan CD, Sokos GG, Pidwell DJ, et al. Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection. Am J Transplant 2009; 9: 2075-2084.
10. Przybylowski P, Balogna M, Radovancevic B., et al. The role of flow cytometry-detected IgG and IgM antidonor antibodies in cardiac allograft recipients. Transplantation 1999; 67: 258-262.
11. Tambur AR, Bray RA, Takemoto S.K., et al. Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection. Transplantation 2000; 70: 1055-1059.
12. Vlad G, Ho EK, Vasilescu E.R., et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and decreased-donor kidney allograft survival. Hum Immunol 2009; 70: 589-594.
13. Kerman RH, Radovancevic R, Allison P.A., et al. Positive flow cytometry crossmatches and HLA antibodies may not be contraindications to heart transplantation. J Heart Lung Transplant 2010; 29: S151.
14. Rose ML, Smith JD Clinical relevance of complement-fixing antibodies in cardiac transplantation. Hum Immunol 2009; 70: 605-609.
15. Bray RA, Gebel HM Strategies for human leukocyte antigen antibody detection. Curr Opin Organ Transplant 2009; 14: 392-397.
16. Kittleson M, Patel J, Reed E., et al. Does MFI quantitation of circulating antibodies correlate with positive cytotoxicity. J Heart Lung Transplant 2010; 29: S152.
17. Kerman R, Stepkowski S, Hoover A., et al. Clinical relevance of crossmatch results, HLA and non HLA AB antibodies for cardiac allograft recipients. J Heart Lung Transplant 2007; 26(SUPPL. 2): S150.
18. Ekong UD, Miller SD, O'Gorman MR. In vitro assays of allosensitization. Pediatr Transplant 2009; 13: 25-34.
19. Morales-Buenrostro LE, Terasaki PI, Marino-Vázquez LA, et al. 'Natural' human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86: 1111-1115.
20. Bingaman AW, Murphey CL, Palma-Vargas J, et al. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation. Transplantation 2008; 86: 1864-1868.
21. Stehlik J, Islam N, Hurst D., et al. Utility of virtual crossmatch in sensitized patients awaiting heart transplantation. J Heart Lung Transplant 2009; 28: 1129-1134.
22. Nikaein A, Cherikh W, Nelson K., et al. Organ procurement and transplantation network/united network for organ sharing histocompatibility committee collaborative study to evaluate prediction of crossmatch results in highly sensitized patients. Transplantation 2009; 87: 557-562.
23. Rhee JK, McGee E, Subacius H., et al. The impact of virtual crossmatch on cardiac allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant 2010; 29: S153.
24. Smith JD, Brunner VM, Jigjidsuren S, et al. Lack of effect of MICA antibodies on graft survival following heart transplantation. Am J Transplant 2009; 9: 1912-1919.
25. Kauke T, Kaczmarek I, Dick A, et al. Anti-Mica antibodies are related to adverse outcome in heart transplant recipients. J Heart Lung Transplant 2009; 28: 305-311.
26. Smith JD, Hamour IM, Burke M.M., et al. A reevaluation of the role of IgM non HLA antibodies in cardiac transplantation. Transplantation 2009; 87: 864-871.
27. Mahesh B, Leong HS, McCormack A, et al. Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am J Pathol 2007; 170: 1415-1427.
28. Mahesh B, Leong HS, Nair K.S., et al. Autoimmunity to vimentin potentiates graft vasculopathy in murine cardiac allografts. Transplantation 2010; 90: 4-13.
29. Drakos SG, Kfoury AG, Kotter J.R., et al. Prior human leukocyte antigen-allosensitization and left ventricular assist device type affect degree of postimplantation human leukocyte antigen-allosensitization. J Heart Lung Transplant 2009; 28: 838-842.
30. Kirsch L, Timmermans T, Van Caenegem O, et al. Allosensitization in bridge to transplant novacor left ventricular assist device patients: analysis of long-term outcomes with regard to acute rejection and chronic allograft vasculopathy. Eur J Cardiothorac Surg 2008; 34: 268-274; discussion 274.
31. Yang J, Schall C, Smith D., et al. HLA sensitization in pediatric pretransplant cardiac patients supported by mechanical assist devices: the utility of luminex. J Heart Lung Transplant 2009; 28: 123-129.
32. John R, Lietz K, Schuster M., et al. Immunologic sensitization in recipients of left ventricular assist devices. J Thorac Cardiovasc Surg 2003; 125: 578-591.
33. Feller E, Sorenson E, Griffith B. Desensitization therapies are ineffective and may increase infection rates in VAD patients. J Heart Lung Transplant 2010; 29: S120.
34. McGee EC, Cotts W, Tambur A.R., et al. Successful bridge to transplant in a highly sensitized patient with a complicated pump pocket infection. J Heart Lung Transplant 2008; 27: 568-571.
35. Taylor DO, Kfoury AG, Pisani B, et al. Antilymphocyte-antibody prophylaxis: review of the adult experience in heart transplantation. Transplant Proc 1997; 29 (8A): 13S-15S.
36. Jordan SC, Tyan D, Stablein D., et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256-3262.
37. John R, Lietz K, Burke E., et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999; 100 (19 SUPPL.): II229-II235.
38. Weston MW, Lopez-Cepero MM, DiChiara L. The prospective use of plasmapheresis and IVIG in sensitized patients prior to heart transplantation. J Heart Lung Transplant 2004; 23: S61-S62.
39. Allison AC, Eugui EM Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
40. Lietz K, John R, Schuster M., et al. Mycophenolate mofetil reduces anti-HLA antibody production and cellular rejection in heart transplant recipients. Transplant Proc 2002; 34: 1828-1829.
41. De Marco T., Damon LE, Colombe B, et al. Successful immunomodulation with intravenous gamma globulin and cyclophosphamide in analloimmunized heart transplant recipient. J Heart Lung Transplant 1997; 16: 360-365.
42. Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 1999; 18: 701-706.
43. Vo AA, Lukovsky M, Toyoda M., et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242-251.
44. Vo AA, Peng A, Toyoda M., et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095-1102.
45. Perry DK, Pollinger HS, Burns J.M., et al. Two novel assays of alloantibody- secreting cells demonstrating resistance to desensitization with IVIG and ratg. Am J Transplant 2008; 8: 133-143.
46. Gonzalez-Stawinski G.V., Davis RD Rituximab as monotherapy for elicited xenoreactive antibody responses. J Heart Lung Transplant 2006; 25: 1462-1466.
47. Leventhal JR, Gallon L, Buckingham M., et al. A prospective, nonrandomized trial of alemtuzumab for desensitization of waiting list candidates with anti-HLA antibodies: an interim analysis. Am J Transplant 2006; 6 (SUPPL. 2): 781.
48. Perry DK, Burns JM, Pollinger H.S., et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201-209.
49. Diwan T, Burns J, Perry D., et al. Effect of proteasome inhibition on alloantibody secreting cells in vivo. Am J Transplant 2009; 9 (SUPPL. 2): 241.
50. Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, et al. Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. Haematologica 2009; 94: 975-983.
51. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754-1761.
52. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555-1561.
53. Patel J, Kittelson M, Reed E., et al. The effectiveness of a standardized desensitization protocol in reducing calculated panel reactive antibodies (cpra) in sensitized heart transplant candidates: does it make sense to desensitize? J Heart Lung Transplant 2010; 29: S103.
54. Kaczmarek I, Deutsch MA, Kauke T, et al. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp Clin Transplant 2008; 6: 229-235.
55. Ensor CR, Cahoon WD, Hess M.L., et al. Induction immunosuppression for orthotopic heart transplantation: a review. Prog Transplant 2009; 19: 333-341; quiz 342.
56. Vo AA, Toyoda M, Peng A., et al. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 2006; 6: 2384-2390.
57. Teuteberg JJ, Shullo MA, Zomak R, et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant 2010; 10: 382-388.
58. Vo AA, Wechsler EA, Wang J, et al. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am J Transplant 2008; 8: 144-149.
59. Clatworthy MR, Watson CJ, Plotnek G, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 360: 2683-2685.
60. Lick SD, Vaidya S, Kollar A.C., et al. Peri-operative alemtuzumab (campath-1 h) and plasmapheresis for high-pra positive lymphocyte crossmatch heart transplant: a strategy to shorten left ventricular assist device support. J Heart Lung Transplant 2008; 27: 1036-1039.
61. Gloor J, Stegall MD Sensitized renal transplant recipients: current protocols and future directions. Nat Rev Nephrol 2010; 6: 297-306.
62. Eckman PM, Thorsgard M, Maurer D., et al. Bortezomib for refractory antibody-mediated cardiac allograft rejection. Clin Transpl 2010: 475-478.
63. Sberro-Soussan R., Zuber J, Suberbielle-Boissel C, et al. Bortezomib as the sole postrenal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010; 10: 681-686.
64. Meister S, Schubert U, Neubert K., et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67: 1783-1792.
65. Rother RP, Arp J, Jiang J., et al. C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients. Am J Transplant 2008; 8: 1129-1142.
66. Pruitt SK, Bollinger RR The effect of soluble complement receptor type 1 on hyperacute allograft rejection. J Surg Res 1991; 50: 350-355.
67. Locke JE, Magro CM, Singer A.L., et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231-235.
68. Stegall MD, Diwan TS, Burns J.M., et al. Prevention of acute humoral rejection with C5 inhibition. Am J Transplant 2009; 9 (SUPPL. 2): 241-242.
69. Cornell LD, Burns JM, Stegall MD Prevention of endothelial activation with C5 inhibition in positive-crossmatch kidney transplants (+xmktx). Am J Transplant 2009; 9 (SUPPL. 2): 304.
70. Olausson M, Mjörnstedt L, Nordén G, et al. Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients. Am J Transplant 2007; 7: 130-136.
71. Ramos EJ, Pollinger HS, Stegall M.D., et al. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007; 7: 402-407.
72. Han M, Rogers JA, Lavingia B, et al. Peripheral blood B cells producing donor-specific HLA antibodies in vitro. Hum Immunol 2009; 70: 29-34.
73. Greenlaw RE, Gardner NJ, Farrar C.A., et al. An antibody combination that targets activated T cells extends graft survival in sensitized recipients. Am J Transplant 2008; 8: 2272-2282.
74. Balin SJ, Platt JL, Cascalho M. Noncognate function of B cells in transplantation. Transpl Int 2009; 22: 593-598.